Newly discovered bacterium may have a role in gum disease
Researchers at the University of Michigan have identified a bacterium normally present in the buccal flora of mice they called NI1060. This bacterium is associated with the development of a model of periodontitis in rats. The researchers found that NI1060 accumulated at sites where gum tissue was damaged and activated a protein in the buccal cavity that stimulates bone-destroying cells. Under normal circumstances, this protein, Nod1, fights harmful bacteria in the body. "Nod1 is a part of our mechanisms of protection against bacterial infection," says corresponding author Noahiro Lnohara, Ph.D., associate professor of research at University of Michigan Health System, Ann Harbor. "It helps us fight infection by recruiting neutrophils, blood cells that act as bacterial killers, and it also removes harmful bacteria during infection." However, in the case of periodontitis, the accumulation of NI1060 stimulates Nod1 to activate neutrophils and osteoclasts, bone-destroying cells in the buccal cavity. "The researchers also noted that while Nod1 regulates the immune system response to NI1060, it does not let NI1060 accumulate in gingival disease sites. Findings from this study highlight the connection between beneficial and harmful bacteria that normally reside in the oral cavity, how the harmful bacteria cause the disease, and how a patient at risk can respond to that bacterium, "says study co-author Dr. William Giannobile, professor of dentistry and chair of the Department of Periodontology and Oral Medicine at the University of Michigan School of Dentistry.
Eating a school lunch taken from a machine may be a breaker, but it also has long-term effects on children's diets. Food sold in the public school automatic machines influences the diet of children who consume them and can affect overall diet and health, according to a recent study. The study, which the authors say is the first to examine this topic with a nationally representative sample, was published in the January issue of the Journal of Adolescent Health .
O (SUS), which will be offered a new hepatitis C drug free of charge. The decision was published in the Federal Official Gazette this Thursday (March 15). in 180 days from this date. The treatment is a combination of two substances (elbasvir and grazoprevir) that treat types 1 and 4 of the virus, so it will inhibit the reproduction of hepatitis C virus so that there is fewer copies in the body, and thus fewer associated symptoms.